Quick Answer
Beta Bionics, Inc. reported Diluted EPS of $1.81 per share (loss) for fiscal year 2025.
Beta Bionics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.81 | +79.0% |
| 2024 | -$8.60 | -3.5% |
| 2023 | -$8.31 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.33 | +77.4% | +15.4% |
| June 30, 2025 | -$0.39 | +83.5% | +58.1% |
| March 31, 2025 | -$0.93 | +55.1% | +36.3% |
| September 30, 2024 | -$1.46 | — | +38.4% |
| June 30, 2024 | -$2.37 | — | -14.5% |
| March 31, 2024 | -$2.07 | — | — |
- Beta Bionics, Inc. showed an increase of +79.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Beta Bionics, Inc.’s diluted eps has grown by 78.2% (from $8.31 per share (loss) to $1.81 per share (loss)).
- The most recent figure is from Beta Bionics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: